US Stock MarketDetailed Quotes

APM Aptorum

  • 3.3300
  • -0.3700-10.00%
Close Jul 19 16:00 ET
  • 3.3500
  • +0.0200+0.60%
Post 16:04 ET
18.22MMarket Cap-5370P/E (TTM)

About Aptorum Company

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.

Company Profile

Company NameAptorum
Listing DateDec 18, 2018
Issue Price15.80
CEOMr. Ian Huen
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address17 Hanover Square
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1S 1BN

Company Executives

  • Name
  • Position
  • Salary
  • Ian Huen
  • Chief Executive Officer and Executive Director
  • 397.37K
  • Charles Bathurst
  • Independent Director
  • 50.11K
  • Dr. Mirko Scherer
  • Independent Director
  • 39.56K
  • Professor Douglas Arner
  • Independent Director
  • 39.56K
  • Dr. Justin Wu
  • Independent Director
  • 39.56K
  • Martin Siu
  • Head of Finance
  • 92.31K


Analyst Rating

No Data

Price Target

No Data

Heat List
Latest Price